Shamburg News · 8-K filed Nov 16, 2026, 9:28 AM EST
Unicycive Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
UNCY · Unicycive Therapeutics, Inc.
- Earnings
- Other event
- Materiality: high
Unicycive Therapeutics, Inc. reported a net loss attributable to common stockholders of $(7.0) million, or $(0.25) per share, for the quarter ended September 30, 2026, compared with $(6.0) million, or $(0.33) per share, a year earlier. The company said R&D expense was $2.2 million and G&A expense was $6.6 million, and that cash, cash equivalents and marketable securities were approximately $59 million as of September 30, 2026. The release also announced FDA acceptance of the oxylanthanum carbonate NDA resubmission with a PDUFA target action date of March 25, 2027.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001213900-26-120261.
Written from the filing by Shamburg Markets. Figures are as reported by the company.